IFN-α is an all and more preferable treatment for diseases like Philadelphia-negative myeloproliferative neoplasms (MPNs), essential thrombocytosis, polycythemia vera (PV) and primary myelofibrosis (PMF) [216,217]. This evidence concerns the gene IFNA2 and acquired polycythemia vera.